Pancreatic carcinogenesis. Clinical implications;Karzinogenese des Pankreaskarzinoms. Klinische Relevanz

Chirurg

Volumn 74, Issue 3, 2003, Pages 165-170

  Schneider, G ^a   Lersch, C ^a   Schmid, R M ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Genetics; Oncogenesis; Pancreatic carcinoma; Therapeutics

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; GEMCITABINE; ISIS 2503; LIGAND; LONAFARNIB; MARIMASTAT; OLIGONUCLEOTIDE; OLOMOUCINE; ONYX 015; PD 0183812; PROTEIN P53; RAS PROTEIN; ROSCOVITINE; SMAD PROTEIN; SMAD4 PROTEIN; VATALANIB; WORTMANNIN; EPIDERMAL GROWTH FACTOR RECEPTOR; SCATTER FACTOR; TUMOR SUPPRESSOR PROTEIN;

CARCINOGENESIS; CELL CYCLE; CLINICAL TRIAL; GENE EXPRESSION; GENETICS; HUMAN; ONCOGENE; ONCOGENE K RAS; PANCREAS CARCINOMA; REVIEW; SOMATIC MUTATION; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; ARTICLE; COMPARATIVE STUDY; FORECASTING; MUTATION; ONCOGENE RAS; PANCREAS TUMOR; PROGNOSIS;

FORECASTING; GENES, P53; GENES, RAS; GENES, TUMOR SUPPRESSOR; HEPATOCYTE GROWTH FACTOR; HUMANS; MUTATION; ONCOGENES; PANCREATIC NEOPLASMS; PROGNOSIS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 0037944178     PISSN: 00094722     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00104-003-0618-6     Document Type: Review

References (79)

1. Abbruzzese J, Rosenberg A, Xiong Q et al. (2001) Phase II study of anti-epidermal growth factor receptor (EGFR) antibody cetuximab (IMC-C225) in combination with gemcitabine in patients with advanced pancreatic cancer. Proc Am Soc Clin Oncol 20:130a (Abstr.518)
2. Adamson P, Marshall CJ, Hall A, Tillbrook PA (1992) Post-translational modifications of p21rho proteins. J Biol Chem 267:20033
3. Almoguera C, Shibata D, Forrester K et al. (1988) Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53:549
4. Apple SK, Hecht JR, Lewin DN et al. (1999) Immunohistochemical evaluation of K-ras, p53, and HER-2/neu expression in hyperplastic, dysplastic, and carcinomatous lesions of the pancreas: evidence for multistep carcinogenesis. Hum Pathol 30:123
5. Arteaga CL (2002) Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin Oncol 29:3
6. Barton CM, Staddon SL, Hughes CM et al. (1991) Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer. Br J Cancer 64:1076
7. Biankin AV, Kench JG, Morey AL et al. (2001) Overexpression of p21 (WAF1/CIP1) is an early event in the development of pancreatic intraepithelial neoplasia. Cancer Res 61:8830
8. Biederer C, Ries S, Brandts CH, Mccormick F (2002) Replication-selective viruses for cancer therapy. J Mol Med 80:163
9. Bloomston M, Zervos EE, Rosemurgy AS 2nd (2002) Matrix metalloproteinases and their role in pancreatic cancer: a review of preclinical studies and clinical trials. Ann Surg Oncol 9:668
10. Bondar VM, Sweeney-Gotsch B, Andreeff M et al. (2002) Inhibition of Phosphatidylinositol 3′-Kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Molecular Cancer Therapeutics 1:989
11. Boschman CR, Stryker S, Reddy JK, Rao MS (1994) Expression of p53 protein in precursor lesions and adenocarcinoma of human pancreas. Am J Pathol 145:1291
12. Bramhall SR, Rosemurgy A, Brown PD et al. (2001) Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol 19:3447
13. Bramhall SR, Schulz J, Nemunaitis J et al. (2002) A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 87:161
14. Bruns CJ, Solorzano CC, Harbison MT et al. (2000) Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 60:2926
15. Bruns CJ, Shrader M, Harbison MT et al. (2002) Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice. Int J Cancer 102:101
16. Burris H, Storniolo AM (1997) Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil. Eur J Cancer 33:S18
17. Burris HA 3rd, Moore MJ, Andersen J et al. (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403
18. Caldas C, Hahn SA, Da Costa LT et al. (1994) Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 8:27
19. Caldas C, Kern SE (1995) K-ras mutation and pancreatic adenocarcinoma. Int J Pancreatol 18:1
20. Crawford HC, Scoggins CR, Washington MK et al. (2002) Matrix metalloproteinase-7 is expressed by pancreatic cancer precursors and regulates acinar-to-ductal metaplasia in exocrine pancreas. J Clin Invest 109:1437
21. Cunningham CC, Holmlund JT, Geary RS et al. (2001) A Phase I trial of H-ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinoma. Cancer 92:1265
22. Day JD, Digiuseppe JA, Yeo C et al. (1996) Immunohistochemical evaluation of HER-2/neu expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms. Hum Pathol 27:119
23. De Bono JS, Rowinsky EK (2002) The ErbB receptor family: a therapeutic target for cancer. Trends Mol Med 8:S19
24. Dugan MC, Dergham ST, Kucway R et al. (1997) HER-2/neu expression in pancreatic adenocarcinoma: relation to tumor differentiation and survival. Pancreas 14:229
25. Ebert M, Yokoyama M, Kobrin MS et al. (1994) Induction and expression of amphiregulin in human pancreatic cancer.Cancer Res 54:3959
26. Friess H, Yamanaka Y, Kobrin MS et al. (1995) Enhanced erbB-3 expression in human pancreatic cancer correlates with tumor progression. Clin Cancer Res 1:1413
27. Fry DW, Bedford DC, Harvey PH et al. (2001) Cell cycle and biochemical effects of PD 0183812. A potent inhibitor of the cyclin D-dependent kinases CDK4 and CDK6. J Biol Chem 276:16617
28. Gansauge S, Gansauge F, Ramadani M et al. (1997) Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis. Cancer Res 57:1634
29. Goldman CK, Kim J, Wong WL et al. (1993) Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol Biol Cell 4:121
30. Goldstein AM, Fraser MC, Struewing JP et al. (1995) Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med 333:970
31. Gorunova L, Hoglund M, Andren-Sandberg AS, et al. (1998) Cytogenetic analysis of pancreatic carcinomas: intratumor heterogeneity and nonrandom pattern of chromosome aberrations. Genes Chromosomes Cancer 23:81
32. Gruis NA, van der Velden PA, Sandkuijl LA et al. (1995) Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds. Nat Genet 10:351
33. Hahn SA, Hoque AT, Moskaluk CA et al. (1996) Homozygous deletion map at 18q21.1 in pancreatic cancer. Cancer Res 56:490
34. Hahn SA, Schutte M, Hoque AT et al. (1996) DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271:350
35. Harada T, Okita K, Shiraishi K et al. (2002) Interglandular cytogenetic heterogeneity detected by comparative genomic hybridization in pancreatic cancer. Cancer Res 62:835
36. Harbour JW, Dean DC (2000) The Rb/E2F pathway: expanding roles and emerging paradigms. Genes Dev 14:2393
37. Heise C, Sampson-Johannes A, Williams A et al. (1997) ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 3:639
38. Hruban RH, van Mansfeld AD, Offerhaus GJ et al. (1993) K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol 143:545
39. Hruban RH, Wilentz RE, Kern SE (2000) Genetic progression in the pancreatic ducts. Am J Pathol 156:1821
40. Hruban RH, Adsay NV, Albores-Saavedra J et al. (2001) Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol 25:579
41. Iseki H, Ko TC, Xue XY et al. (1998) A novel strategy for inhibiting growth of human pancreatic cancer cells by blocking cyclin-dependent kinase activity. J Gastrointest Surg 2:36
42. James GL, Goldstein JL, Brown MS (1995) Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro. J Biol Chem 270:6221
43. Kobrin MS, Funatomi H, Friess H et al. (1994) Induction and expression of heparin-binding EGF-like growth factor in human pancreatic cancer. Biochem Biophys Res Commun 202:1705
44. Korc M, Chandrasekar B, Yamanaka Y et al. (1992) Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha. J Clin Invest 90:1352
45. Landis SH, Murray T, Bolden S, Wingo PA (1998) Cancer statistics, 1998. CA Cancer J Clin 48:6
46. Lerner EC, Qian Y, Blaskovich MA et al. (1995) Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes. J Biol Chem 270:26802
47. Lersch C, van Cutsem E, Amado R et al. (2001) Randomised phase II study of SCH66336 and gemcitabine in the treatment of metastatic adenocarcinoma of the pancreas. Proc ASCO 20:153a (Abstr.608)
48. Levine AJ (1997) p53, the cellular gatekeeper for growth and division. Cell 88:323
49. Massague J, Blain SW, Lo RS (2000) TGFbeta signaling in growth control, cancer, and heritable disorders. Cell 103:295
50. Mulvihill S, Warren R, Venook A et al. (2001) Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial. Gene Ther 8:308
51. Nakada Y, Saito S, Ohzawa K et al. (2001) Antisense oligonucleotides specific to mutated K-ras genes inhibit invasiveness of human pancreatic cancer cell lines. Pancreatology 1:314
52. Overholser JP, Prewett MC, Hooper AT et al. (2000) Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice. Cancer 89:74
53. Redston MS, Caldas C, Seymour AB et al. (1994) p53 mutations in pancreatic carcinoma and evidence of common involvement of homo copolymer tracts in DNA microdeletions. Cancer Res 54:3025
54. Rothenberg ML, Moore MJ, Cripps MC et al. (1996) A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 7:347
55. Rozenblum E, Schutte M, Goggins M et al. (1997) Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 57:1731
56. Schreiber AB, Winkler ME, Derynck R (1986) Transforming growth factor-alpha: a more potent angiogenic mediator than epidermal growth factor. Science 232:1250
57. Schutte M, Hruban RH, Hedrick L et al. (1996) DPC4 gene in various tumor types. Cancer Res 56:2527
58. Schutte M, Hruban RH, Geradts J et al. (1997) Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res 57:3126
59. Schwarte-Waldhoff I, Volpert OV, Bouck NP et al. (2000) Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis. Proc Natl Acad Sci USA 97:9624
60. Sepp-Lorenzino L, Rosen N (1998) A farnesyl-protein transferase inhibitor induces p21 expression and G1 block in p53 wild type tumor cells. J Biol Chem 273:20243
61. Serrano M, Lin AW, McCurrach ME et al. (1997) Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88:593
62. Seufferlein T, van Lint J, Liptay S et al. (1999) Transforming growth factor alpha activates Ha-Ras in human pancreatic cancer cells with Ki-ras mutations. Gastroenterology 116:1441
63. Sherr CJ (2001) The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2:731
64. Shields JM, Pruitt K, McFall A et al. (2000) Understanding Ras: "it ain't over'til it's over". Trends Cell Biol 10:147
65. Shirasawa S, Furuse M, Yokoyama N, Sasazuki T (1993) Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 260:85
66. Smith JJ, Derynck R, Korc M (1987) Production of transforming growth factor alpha in human pancreatic cancer cells: evidence for a superagonist autocrine cycle. Proc Natl Acad Sci USA 84:7567
67. Solorzano CC, Baker CH, Bruns CJ et al. (2001) Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Cancer Biother Radiopharm 16:359
68. Solorzano CC, Baker CH, Tsan R et al. (2001) Optimization for the blockade of epidermal growth factor receptor signaling for therapy of human pancreatic carcinoma. Clin Cancer Res 7:2563
69. Soni R, O'Reilly T, Furet P et al. (2001) Selective in vivo and in vitro effects of a small molecule inhibitor of cyclin-dependent kinase 4. J Natl Cancer Inst 93:436
70. Tarbe N, Evtimova V, Burtscher H et al. (2001) Transcriptional profiling of cell lines derived from an orthotopic pancreatic tumor model reveals metastasis-associated genes. Anticancer Res 21:3221
71. Tascilar M, Skinner HG, Rosty C et al. (2001) The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin Cancer Res 7:4115
72. Terhune PG, Phifer DM, Tosteson TD, Longnecker DS (1998) K-ras mutation in focal proliferative lesions of human pancreas. Cancer Epidemiol Biomarkers Prev 7:515
73. Tsuchida T, Kiljima H, Hori S et al. (2000) Adenovirus-mediated anti-K-ras ribozyme induces apoptosis and growth suppression of human pancreatic carcinoma. Cancer Gene Ther 7:373
74. Wagner M, Greten FR, Weber CK et al. (2001) A murine tumor progression model for pancreatic cancer recapitulating the genetic alterations of the human disease. Genes Dev 15:286
75. Whelan AJ, Bartsch D, Goodfellow PJ (1995) Brief report: a familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. N Engl J Med 333:975
76. Wilentz RE, Iacobuzio-Donahue CA, Argani P et al. (2000) Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res 60:2002
77. Yamanaka Y, Friess H, Kobrin MS et al. (1993) Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res 13:565
78. Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127
79. Zhang Z, Wang Y, Vikis HG et al. (2001) Wildtype Kras2 can inhibit lung carcinogenesis in mice. Nat Genet 29:25